SCHEMBL4299657

SCHEMBL4299657

Cc1ccc(C2C(C(=O)c3ccc(Cl)cc3)=C(O)C(=O)N2c2ccc3[nH]cnc3c2)o1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
HIF1A Q16665 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
PPARG P37231 2/20 0.43
NCOA2 Q15596 1/20 0.43
PKM P14618 2/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 2/20 0.40
KMT2A Q03164 2/20 0.40
QPCT Q16769 2/20 0.39
CCR1 P32246 1/20 0.37
CCR2 P41597 1/20 0.37
RXFP1 Q9HBX9 4/20 0.37
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
NCOR2 Q9Y618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4303946 0.86 MEN1 (0.44) ALDH1A1PKMMEN1POLBKMT2A
SCHEMBL4291137 0.83 ALDH1A1 (0.53) ALDH1A1HIF1AMEN1POLBKMT2A
SCHEMBL3817951 0.82 CCR1 (0.38) ALDH1A1HIF1AL3MBTL1PKMMEN1
SCHEMBL4299447 0.82 MEN1 (0.37) ALDH1A1HIF1AL3MBTL1PKMMEN1
SCHEMBL4300367 0.81 CCR1 (0.40) ALDH1A1L3MBTL1PKMMEN1POLB
SCHEMBL4306251 0.80 P2RX3 (0.40) ALDH1A1HIF1AL3MBTL1PKMMEN1
SCHEMBL4298179 0.79 ALDH1A1 (0.32) ALDH1A1PPARGNCOA2PKMMEN1
SCHEMBL4302300 0.76 HPGD (0.41) ALDH1A1HIF1AL3MBTL1MEN1KMT2A
SCHEMBL4301254 0.76 MEN1 (0.40) ALDH1A1HIF1AMEN1KMT2AQPCT
SCHEMBL4299794 0.75 QPCT (0.38) ALDH1A1MEN1POLBKMT2AQPCT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089383-B1 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES PROBIODRUG AG (DE) 2015-09-16 EP claimed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US claimed
EP-2089383-B1 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES PROBIODRUG AG (DE) 2015-09-16 EP disclosed
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US disclosed
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
WO-2008055945-A1 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES PROBIODRUG AG (DE) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL ALDH1A1 896/4885HIF1A 1369/4885L3MBTL1 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.